Conference Coverage

Evaluation of Cortical Lesions Could Improve Diagnosis of MS


 

References

Paolo Preziosa, MD

LONDON—Evaluation of cortical lesions improves specificity of the diagnostic criteria for multiple sclerosis (MS), according to research presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Assessment of cortical lesions, in concert with current McDonald criteria, also preserved a high level of diagnostic sensitivity and accuracy in a multicentric cohort of patients with clinically isolated syndrome, reported Paolo Preziosa, MD, Neuroimaging Research Unit at the Institute of Experimental Neurology and Division of Neuroscience at San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, and his research colleagues.

Since the publication of the 2010 revised McDonald criteria, new data regarding the application of MRI for the diagnosis of MS have become available. In a single-center study, adding the assessment of cortical lesions has been shown to modify the diagnostic algorithm resulting in higher specificity.

In the present study, Dr. Preziosa and colleagues sought to test the performance of different sets of imaging criteria, including the assessment of cortical lesions, for the development of MS in a multicentric cohort of patients with clinically isolated syndrome.

The researchers analyzed brain double inversion recovery and brain and cord T2-weighted and post-contrast T1-weighted sequences acquired from 72 patients with clinically isolated syndrome from five European centers (Barcelona, Belgrade, Mainz, Milan, and Verona) within three months and after 12 months from disease onset. Patients were followed clinically for 24 or more months or until the development of clinically defined MS. Median follow-up was 24.2 months. Sensitivity, specificity, and accuracy of the different dissemination in space MRI criteria for the development of MS were tested.

Pages

Recommended Reading

Ocrelizumab May Be More Effective for Relapsing-Remitting MS Than Interferon
ICYMI Multiple Sclerosis
Can Stem Cells Halt Progression of MS?
ICYMI Multiple Sclerosis
Siponimod shows promise through 24 months in relapsing-remitting MS
ICYMI Multiple Sclerosis
Peter Chin, MD
ICYMI Multiple Sclerosis
Is Biotin an Effective Treatment for Progressive MS?
ICYMI Multiple Sclerosis
Abatacept fails to provide benefit in relapsing-remitting MS
ICYMI Multiple Sclerosis
Harold Moses Jr, MD
ICYMI Multiple Sclerosis
Abatacept Fails to Provide Benefits in Relapsing MS
ICYMI Multiple Sclerosis
Multiple Sclerosis Is Associated With Changes in the Gut Microbiome
ICYMI Multiple Sclerosis
Th17 Cells Are Activated in the Gut of Patients With MS
ICYMI Multiple Sclerosis